The direct-to-consumer genetic testing fog
By Timothy Caulfield,
Policy Options
| 05. 25. 2017
There is a direct-to-consumer (DTC) genetic testing company that gives parents the opportunity to uncover their kids’ “hidden” talents. You can (allegedly) find out if your child has the genetic propensity for things like dancing, passion, intelligence, self-reflection and even teenage romance. The company suggests that this information is valuable because it “will help you take control and maximize the development of your child,” including personalizing “discipline strategies” and career guidance so you can maximize your “returns on your investments” (because, let’s face it, kids are a financial sinkhole).
This is all scientifically absurd, of course. And any product based on the principle of having your kids do what you tell them seems destined to disappoint. Has the marketing team ever met a teenager?
But, despite the lack of evidence, these kooky kinds of DTC services continue to proliferate and have become big business. In China, for example, there has been a rise in genetic testing as many parents take their kids to “talent detection” facilities in the hope of gleaning information to inform education and career decisions.
There...
Related Articles
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
By Pam Belluck and Carl Zimmer, The New York Times | 11.19.2025
Gene-editing therapies offer great hope for treating rare diseases, but they face big hurdles: the tremendous time and resources involved in devising a treatment that might only apply to a small number of patients.
A study published on Wednesday...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...